Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to JP¥1,616, the stock trades at a trailing P/E ratio of 62.4x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total loss to shareholders of 45% over the past year. 공시 • Jun 03
Heartseed Inc. to Report Q2, 2026 Results on Aug 14, 2026 Heartseed Inc. announced that they will report Q2, 2026 results on Aug 14, 2026 Valuation Update With 7 Day Price Move • May 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to JP¥1,531, the stock trades at a trailing P/E ratio of 59.1x. Average trailing P/E is 36x in the Biotechs industry in Asia. Total loss to shareholders of 41% over the past year. 공시 • May 09
Heartseed Inc. to Report Q1, 2026 Results on May 15, 2026 Heartseed Inc. announced that they will report Q1, 2026 results on May 15, 2026 공시 • Feb 14
Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026 Heartseed Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects net sales of JPY 451 million, Operating loss of JPY 2,207 million, Loss of JPY 2,158 million and Basic loss per share of JPY 95.58. 공시 • Feb 13
Heartseed Inc., Annual General Meeting, Mar 27, 2026 Heartseed Inc., Annual General Meeting, Mar 27, 2026. 공시 • Dec 27
Heartseed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026 Heartseed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥1,806, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 38x in the Biotechs industry in Asia. Total loss to shareholders of 29% over the past year. New Risk • Dec 04
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 37% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 37% per year for the foreseeable future. Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to JP¥1,727, the stock trades at a trailing P/E ratio of 75.8x. Average trailing P/E is 63x in the Biotechs industry in Japan. Total returns to shareholders of 17% over the past year. Buy Or Sell Opportunity • Oct 03
Now 27% overvalued Over the last 90 days, the stock has fallen 45% to JP¥1,526. The fair value is estimated to be JP¥1,198, however this is not to be taken as a sell recommendation but rather should be used as a guide only. 공시 • Jul 31
Heartseed Inc. to Report Q3, 2025 Results on Sep 11, 2025 Heartseed Inc. announced that they will report Q3, 2025 results on Sep 11, 2025 공시 • Apr 23
Heartseed Inc. to Report Q2, 2025 Results on Jun 12, 2025 Heartseed Inc. announced that they will report Q2, 2025 results on Jun 12, 2025 공시 • Feb 03
Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial Using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart Failure Heartseed Inc. announced the completion of patient enrollment for the 5th patient in high-dose arm, marking the 10th and final patient enrolled in its Phase I/II clinical trial (LAPiS Study) for HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid product for advanced heart failure due to ischaemic heart disease. As stated in the press release dated October 1, 2024, the Safety Monitoring Committee reviewed the safety data of the first patient in the high-dose cohort (150 million cardiomyocytes) of the LAPiS Study and recommended the continuation of enrollment for the high-dose group. Following this, patient dosing progressed smoothly, and the enrollment of all patients in the LAPiS Study has now been completed. About HS-001 and LAPiS Study: HS-001, is an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte product formulated in spheroids. The micro-tissue-like spheroid preparation increases retention rate and viability of the cell graft. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration during open heart surgery. There are two expected mechanisms of action. Firstly, that the transplanted cardiomyocytes electrically couple with the patient's myocardium, improving cardiac output by remuscularization. Second, that secretion of angiogenic factors from the graft causes new blood vessel development around the transplant site (neovascularization). The LAPiS Study is a 52-week, phase 1/2, open-label, dose-escalation trial designed to evaluate the safety and efficacy of HS-001 in patients with advanced heart failure caused by ischaemic heart disease. Conducted at multiple sites in Japan, the study has successfully completed enrollment of 10 patients, divided into two cohorts: 5 in the low-dose group (50 million cardiomyocytes) and 5 in the high-dose group (150 million cardiomyocytes). HS-001 was transplanted into the diseased heart during scheduled open-heart surgeries (coronary artery bypass grafting). The primary endpoint of the study is safety at 26 weeks post-transplantation. Secondary efficacy endpoints, assessed at 26 and 52 weeks, include Left Ventricular Ejection Fraction and myocardial wall motion. 공시 • Jan 28
Heartseed Inc. to Report Q1, 2025 Results on Mar 13, 2025 Heartseed Inc. announced that they will report Q1, 2025 results on Mar 13, 2025 공시 • Dec 13
Heartseed Inc., Annual General Meeting, Jan 24, 2025 Heartseed Inc., Annual General Meeting, Jan 24, 2025. 공시 • Oct 23
Heartseed Inc. to Report Fiscal Year 2024 Results on Dec 12, 2024 Heartseed Inc. announced that they will report fiscal year 2024 results on Dec 12, 2024 공시 • Oct 18
Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024 Heartseed Inc. revised earnings guidance for the fiscal year ending October 31, 2024. For the year, the company expects net sales of JPY 874 million compared to Previous forecast of JPY 153 million, Operating loss of JPY 1,059 million compared to Previous forecast of JPY 1,965 million, net income of JPY 891 million compared to Previous forecast of JPY 1,798 million, and Net loss Per Shares of JPY 54.32 compared to Previous forecast of JPY 109.09. 공시 • Sep 13
Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024 Heartseed Inc. provided earnings guidance for the fiscal year ending October 31, 2024. For the fiscal year, the company expected net sales of JPY 153 million, Operating loss of JPY 1,965 million, Net loss of JPY 1,798 million and Net loss per share of JPY 109.09. 공시 • Aug 10
Heartseed Inc. to Report Q3, 2024 Results on Sep 12, 2024 Heartseed Inc. announced that they will report Q3, 2024 results on Sep 12, 2024 공시 • Aug 01
Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion. Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,413,700
Price\Range: ¥1160
Discount Per Security: ¥92.8
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 388,000
Price\Range: ¥1160
Discount Per Security: ¥92.8
Transaction Features: Sponsor Backed Offering Board Change • Jul 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Outside Director Toshiharu Furukawa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
